✦ LIBER ✦

Time to reevaluate clinical trials for mucinous ovarian cancer

✍ Scribed by Michelle L. Harrison; Martin E. Gore

Book ID: 118624890
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 54 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(07)70047-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Consolidation strategies in ovarian canc

Consolidation strategies in ovarian cancer: Observations for future clinical trials

✍ Paul Sabbatini; David Spriggs; Carol Aghajanian; Martee Hensley; William Tew; Ja 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 366 KB

Cancer Cachexia: It’s Time for More Clin

Cancer Cachexia: It’s Time for More Clinical Trials

✍ Maurizio Bossola; Fabio Pacelli; Antonio Tortorelli; Giovan Battista Doglietto 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 274 KB

Access to cancer care and clinical trial

Access to cancer care and clinical trials: A time for reappraisal

✍ Carolyn D. Rurtowicz; Michael L. Herman 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 148 KB

Clinical trials and future potential of

Clinical trials and future potential of targeted therapy for ovarian cancer

✍ Itamochi, Hiroaki; Kigawa, Junzo 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 274 KB

Clinical trials and future potential of

Clinical trials and future potential of targeted therapy for ovarian cancer

✍ Itamochi, Hiroaki; Kigawa, Junzo 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 274 KB

Ovarian cancer is the leading cause of death in women with gynecological cancer. Most patients are diagnosed at an advanced stage with a poor prognosis. Currently, surgical tumor debulking followed by chemotherapy based on platinum and taxane is the standard treatment for advanced disease. However,

Time to include high-risk early ovarian

Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer

✍ Ignace Vergote; Frederic Amant 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 80 KB